Which medications should be avoided in a patient allergic to perflutren lipid microsphere contrast agents such as Definity (perflutren), Lumason (perflutren), and Optison (perflutren protein‑type A)?

Medications to Avoid with Perflutren Lipid Microsphere Allergy

If you have a documented allergy to perflutren lipid microsphere contrast agents, you must avoid all perflutren-containing ultrasound contrast agents, including Definity (perflutren lipid microsphere), Lumason/Luminity (perflutren lipid microsphere), and Optison (perflutren protein-type A microsphere). 1

Absolute Contraindications

All Perflutren-Based Ultrasound Contrast Agents

• Definity (perflutren lipid microsphere) is absolutely contraindicated in patients with known or suspected hypersensitivity to perflutren lipid microsphere or its components. 1

• Lumason/Luminity (perflutren lipid microsphere) and Optison (perflutren protein-type A) are contraindicated in patients with known hypersensitivity to these agents. 2

• These agents share the same active ingredient (perflutren/octafluoropropane gas) and have documented cross-reactivity risk. 3, 2

Component-Specific Considerations

Polyethylene Glycol (PEG) Allergy

• Definity contains PEG (polyethylene glycol), which may increase the risk of serious reactions including death in patients with prior PEG hypersensitivity. 1

• If your allergy is specifically to PEG rather than perflutren itself, you must also avoid:

  • Certain colonoscopy bowel preparations 1, 4
  • PEG-containing laxatives 1, 4
  • Other PEG-containing medications 4

• Lumason/SonoVue and Luminity are lipid-based agents that are contraindicated in patients with PEG allergy or PEG-containing product hypersensitivity. 4

• However, recent case reports demonstrate that anaphylaxis to Definity can occur from non-PEGylated components, meaning the perflutren or lipid shell itself may be the culprit. 5

Blood Product Allergy (Optison-Specific)

• Optison contains human albumin (protein-type A), making it contraindicated in patients with hypersensitivity to blood, blood products, or albumin. 3, 2

• If you have a blood product allergy, Optison is specifically contraindicated even if other perflutren agents might theoretically be tolerated. 3

Clinical Management Algorithm

If Perflutren Allergy is Documented:

1. Document the specific agent and reaction in the electronic medical record, including exact symptoms and timing. 6

2. Avoid all perflutren-containing contrast agents (Definity, Lumason/Luminity, Optison) regardless of which specific agent caused the initial reaction. 2

3. Consider alternative imaging modalities that do not require ultrasound contrast enhancement. 6

4. If contrast echocardiography is absolutely necessary, there are no FDA-approved alternative ultrasound contrast agents in the same class that would be safe—all available agents contain perflutren. 2

If PEG Allergy is Suspected:

1. Clinically assess for prior reactions to PEG-containing products such as bowel preparations or laxatives before any perflutren agent administration. 1

2. Consider allergy testing with skin prick and intradermal testing to differentiate PEG allergy from perflutren/lipid component allergy. 5

3. If PEG is confirmed as the allergen, all lipid-based ultrasound contrast agents (SonoVue, Lumason, Luminity, Definity) remain contraindicated. 4

Important Caveats

• Cross-reactivity between agents is assumed given the shared perflutren component, even though the lipid shells differ slightly between products. 2

• Anaphylaxis can occur on first exposure without prior sensitization, so a negative history does not guarantee safety. 1, 5, 7

• Severe reactions are rare (0.005%–0.015% incidence), but when they occur they can be life-threatening, including death, shock, bronchospasm, and angioedema. 2, 8

• Emergency equipment must be immediately available whenever these agents are used, including antihistamines, corticosteroids, and epinephrine. 2, 8